emergence kras mutations acquired resistance anti-egfr therapy colorectal cancer
main limitation therapies selectively target kinase signalling pathways emergence secondary drug resistance cetuximab monoclonal antibody binds extracellular domain epidermal growth factor receptor egfr effective subset kras wild-type metastatic colorectal cancers initial response secondary resistance invariably ensues thereby limiting clinical benefit drug molecular bases secondary resistance cetuximab colorectal cancer poorly understood- show molecular alterations instances point mutations kras causally associated onset acquired resistance anti-egfr treatment colorectal cancers expression mutant kras control endogenous gene promoter sufficient confer cetuximab resistance resistant cells remained sensitive combinatorial inhibition egfr mitogen-activated protein-kinase kinase mek analysis metastases patients developed resistance cetuximab panitumumab showed emergence kras amplification one sample acquisition secondary kras mutations % cases kras mutant alleles detectable blood cetuximab-treated patients early months radiographic documentation disease progression summary results identify kras mutations frequent drivers acquired resistance cetuximab colorectal cancers indicate emergence kras mutant clones can detected non-invasively months radiographic progression suggest early initiation mek inhibitor rational strategy delaying reversing drug resistance
